Dr. Sharon Moe
Add to your Care-Team
Dr. Sharon Moe
Dr. Sharon Moe
Internal Medicine - Nephrology & Dialysis
I specialize in
Internal Medicine - Nephrology & Dialysis
I have been in practice
My answers and insights have
Helped 20 people
Here are kind words from others
This Thanksgiving, I wanted to share my appreciation for all that you do! Thank you, doctor! :)
I was educated and trained at
Medical / Graduate School
University of Illinois College of Medicine
University of Illinois, Urbana-Champaign
Rebuttal: PTH--A Particularly Tricky Hormone: Why Measure It at All in Kidney Patients?
Clin J Am Soc Nephrol., Nov (2012)
The Case for Routine Parathyroid Hormone Monitoring.
Clin J Am Soc Nephrol., Oct (2012)
Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study.
PLoS ONE., 7(9):e45716 (2012)
Skeletal effects of zoledronic acid in an animal model of chronic kidney disease.
Osteoporos Int., Aug (2012)
Calcium builds strong bones, and more is better--correct? Well, maybe not.
Clin J Am Soc Nephrol., Nov;7(11):1877-83 (2012)
Gentamicin pharmacokinetics and pharmacodynamics during short-daily hemodialysis.
Am. J. Nephrol., 36(2):144-50 (2012)
Reimbursement of dialysis: a comparison of seven countries.
J. Am. Soc. Nephrol., Aug;23(8):1291-8 (2012)
Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.
Nephrol. Dial. Transplant., Jul;27(7):2872-9 (2012)
Klotho: a master regulator of cardiovascular disease?
Circulation., May;125(18):2181-3 (2012)
Vascular calcification: pathophysiology and risk factors.
Curr. Hypertens. Rep., Jun;14(3):228-37 (2012)
CKD-mineral and bone disorder: core curriculum 2011.
Am. J. Kidney Dis., Dec;58(6):1022-36 (2011)
The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
J. Bone Miner. Res., Nov;26(11):2672-81 (2011)
Activation of arterial matrix metalloproteinases leads to vascular calcification in chronic kidney disease.
Am. J. Nephrol., 34(3):211-9 (2011)
Optimal vitamin D, calcitriol, and vitamin D analog replacement in chronic kidney disease: to D or not to D: that is the question.
Curr. Opin. Nephrol. Hypertens., Jul;20(4):354-9 (2011)
Calcimimetics inhibit renal pathology in rodent nephronophthisis.
Kidney Int., Sep;80(6):612-9 (2011)
Efficacy of sodium thiosulfate for the treatment for calciphylaxis.
Clin. Nephrol., Jun;75(6):485-90 (2011)
Direct effects of phosphate on vascular cell function.
Adv Chronic Kidney Dis., Mar;18(2):105-12 (2011)
Children with chronic kidney disease: are they insured as adults?
Pediatr. Nephrol., Jun;26(6):995-6 (2011)
The KDIGO guideline on dialysate calcium and patient outcomes: need for hard evidence.
Kidney Int., Feb;79(4):478; author reply 478-9 (2011)
Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease.
Clin J Am Soc Nephrol., Feb;6(2):257-64 (2011)
Confusion on the complexity of calcium balance.
Semin Dial., 23(5):492-7 (2010 Sep-Oct)
Oral phosphate binders in patients with kidney failure.
N. Engl. J. Med., Sep;363(10):990; author reply 990 (2010)
Hepatitis C increases the risk of progression of chronic kidney disease in patients with glomerulonephritis.
Am. J. Nephrol., 32(4):311-6 (2010)
Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysis.
Clin J Am Soc Nephrol., Nov;5(11):1981-7 (2010)
RhoA/Rho kinase (ROCK) alters fetuin-A uptake and regulates calcification in bovine vascular smooth muscle cells (BVSMC).
Am. J. Physiol. Renal Physiol., Sep;299(3):F674-80 (2010)
All research does not a guideline make!
Am. J. Kidney Dis., Apr;55(4):631-4 (2010)
A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease.
Clin J Am Soc Nephrol., Feb;5(2):299-306 (2010)
Verapamil inhibits calcification and matrix vesicle activity of bovine vascular smooth muscle cells.
Kidney Int., Mar;77(5):436-42 (2010)
Review article: Chronic kidney disease-mineral bone disorder: have we got the assays right?
Nephrology (Carlton)., Jun;14(4):374-82 (2009)
Medication changes based on echocardiography in dialysis patients.
Hemodial Int., Oct;13(4):472-8 (2009)
Vascular calcification: the three-hit model.
J. Am. Soc. Nephrol., Jun;20(6):1162-4 (2009)
Calcimimetic inhibits late-stage cyst growth in ADPKD.
J. Am. Soc. Nephrol., Jul;20(7):1527-32 (2009)
R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD).
Nephrol. Dial. Transplant., Aug;24(8):2371-7 (2009)
Improving global outcomes in mineral and bone disorders.
Clin J Am Soc Nephrol., Nov;3 Suppl 3:S127-30 (2008)
A rat model of chronic kidney disease-mineral bone disorder.
Kidney Int., Jan;75(2):176-84 (2009)
Annexin-mediated matrix vesicle calcification in vascular smooth muscle cells.
J. Bone Miner. Res., Nov;23(11):1798-805 (2008)
Precision of biomarkers to define chronic inflammation in CKD.
Am. J. Nephrol., 28(5):808-12 (2008)
Disorders involving calcium, phosphorus, and magnesium.
Prim. Care., Jun;35(2):215-37, v-vi (2008)
Association of hepatitis C virus infection with prevalence and development of kidney disease.
Am. J. Kidney Dis., Jun;51(6):885-92 (2008)
Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study.
Am. J. Kidney Dis., Jun;51(6):987-95 (2008)
Vitamin D, cardiovascular disease, and survival in dialysis patients.
J. Bone Miner. Res., Dec;22 Suppl 2:V95-9 (2007)
Mechanisms of vascular calcification in chronic kidney disease.
J. Am. Soc. Nephrol., Feb;19(2):213-6 (2008)
The case against calcium-based phosphate binders.
Clin J Am Soc Nephrol., Jul;1(4):697-703 (2006)
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview.
Clin J Am Soc Nephrol., Sep;2(5):898-905 (2007)
Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients--a pilot study.
Nephrol. Dial. Transplant., Dec;22(12):3561-7 (2007)
Management of chronic kidney disease mineral-bone disorder.
Adv Chronic Kidney Dis., Jan;14(1):44-53 (2007)
Chronic kidney disease-mineral-bone disorder: a new paradigm.
Adv Chronic Kidney Dis., Jan;14(1):3-12 (2007)
Management of chronic kidney disease-mineral bone disorder.
Adv Chronic Kidney Dis., Jan;14(1):2 (2007)
Uremic vascular calcification.
J. Investig. Med., Nov;54(7):380-4 (2006)
Vascular calcification: Hardening of the evidence.
Kidney Int., Nov;70(9):1535-7 (2006)
High glucose increases the expression of Cbfa1 and BMP-2 and enhances the calcification of vascular smooth muscle cells.
Nephrol. Dial. Transplant., Dec;21(12):3435-42 (2006)
Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovasc
Hypertension., Oct;48(4):751-5 (2006)
Fetuin-A uptake in bovine vascular smooth muscle cells is calcium dependent and mediated by annexins.
Am. J. Physiol. Renal Physiol., Feb;292(2):F599-606 (2007)
Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovasc
Circulation., Sep;114(10):1083-7 (2006)
Vascular calcification and renal osteodystrophy relationship in chronic kidney disease.
Eur. J. Clin. Invest., Aug;36 Suppl 2:51-62 (2006)
Fish consumption and omega-3 fatty acid status and determinants in long-term hemodialysis.
Am. J. Kidney Dis., Jun;47(6):1064-71 (2006)
The role of vitamin D in vascular calcification in chronic kidney disease.
Semin Dial., 18(4):307-14 (2005 Jul-Aug)
Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Nephrol. Dial. Transplant., Oct;20(10):2186-93 (2005)
Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States.
Am. J. Kidney Dis., Jun;45(6):1026-33 (2005)
Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD).
Kidney Int., Jun;67(6):2295-304 (2005)
[Vascular calcification in end stage renal disease].
Clin Calcium., Oct;12(10):1417-22 (2002)
Disorders of calcium, phosphorus, and magnesium.
Am. J. Kidney Dis., Jan;45(1):213-8 (2005)
Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.
Kidney Int., Feb;67(2):760-71 (2005)
Calcification or classification?
J. Am. Soc. Nephrol., Feb;16(2):293-5 (2005)
Cinacalcet hydrochloride: a viewpoint by Sharon M. Moe.
Drugs., 65(2):282-3 (2005)
Inflammation and vascular calcification.
Blood Purif., 23(1):64-71 (2005)
Semin. Nephrol., Sep;24(5):413-6 (2004)
Pathophysiology of vascular calcification in chronic kidney disease.
Circ. Res., Sep;95(6):560-7 (2004)
Natural history of vascular calcification in dialysis and transplant patients.
Nephrol. Dial. Transplant., Sep;19(9):2387-93 (2004)
Management of renal osteodystrophy in peritoneal dialysis patients.
Perit Dial Int., 24(3):209-16 (2004 May-Jun)
Calciphylaxis and vascular calcification: a continuum of extra-skeletal osteogenesis.
Pediatr. Nephrol., Oct;18(10):969-75 (2003)
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
N. Engl. J. Med., Apr;350(15):1516-25 (2004)
A bridge to improving healthcare outcomes and quality of life.
Am. J. Kidney Dis., Mar;43(3):552-7 (2004)
Disturbances of bone and mineral metabolism in chronic kidney disease: an international initiative to improve diagnosis and treatment.
Nephrol. Dial. Transplant., Mar;19(3):534-6 (2004)
Vascular calcification in chronic kidney disease.
Semin. Nephrol., Jan;24(1):61-8 (2004)
Introduction. Renal osteodystrophy.
Semin. Nephrol., Jan;24(1):1-2 (2004)
Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin.
Am. J. Kidney Dis., Dec;42(6):1253-9 (2003)
Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product.
Am. J. Nephrol., 23(6):369-79 (2003 Nov-Dec)
Identity and localization of advanced glycation end products on human beta2-microglobulin using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
Anal. Biochem., Mar;314(2):322-5 (2003)
Arterial calcification in diabetes.
Curr. Diab. Rep., Feb;3(1):28-32 (2003)
Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels.
Kidney Int., Mar;63(3):1003-11 (2003)
Vascular calcification in dialysis patients: pathogenesis and consequences.
Am. J. Kidney Dis., Mar;41(3 Suppl 1):S96-9 (2003)
Cellular uptake of beta2M and AGE-beta2M in synovial fibroblasts and macrophages.
Nephrol. Dial. Transplant., Jan;18(1):46-53 (2003)
Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells.
Kidney Int., Nov;62(5):1724-31 (2002)
Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca x P product and aggressive wound care.
Clin. Nephrol., Sep;58(3):238-43 (2002)
Current issues in the management of secondary hyperparathyroidism and bone disease.
Perit Dial Int., 21 Suppl 3:S241-6 (2001)
Signal transduction of beta2m-induced expression of VCAM-1 and COX-2 in synovial fibroblasts.
Kidney Int., Feb;61(2):414-24 (2002)
The role of the synovium and cartilage in the pathogenesis of beta(2)-microglobulin amyloidosis.
Semin Dial., 14(2):127-30 (2001 Mar-Apr)
Small and middle molecular weight solute clearance in nocturnal intermittent peritoneal dialysis.
Perit Dial Int., 19(6):534-9 (1999 Nov-Dec)
Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial.
Nephrol. Dial. Transplant., May;13(5):1234-41 (1998)
The treatment of steroid-induced bone loss in transplantation.
Curr. Opin. Nephrol. Hypertens., Nov;6(6):544-9 (1997)
Dr. Sharon Moe F